top of page
Podcast Header (17).png

EPISODE 40: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM




Download a Transcript of this Episode >>>

 

ABOUT THIS EPISODE



In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community.





 

MEET DR. GUILLAUME PEGNA



Dr. Pegna is a medical oncologist specializing in caring for adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas, as well as other gastrointestinal cancers.


Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient and supporting them through their treatment journeys.


 

TOP 10 ABSTRACTS AT THE 2024 NANETS SYMPOSIUM:


View the abstracts in the NANETS 2024 Symposium Abstract Guide


Improving our understanding of PRRT/optimizing therapy:


  1. Mosalem et al. Abstract C-19 Safety of Lutetium-177 DOTATATE Treatment in Patients with Advanced Neuroendocrine Tumors and Extensive/ Innumerable Bone Metastases

  2. Singh and Iyer et al. Abstract O-13 Prevalence of CHIP Mutations in patients with Neuroendocrine Tumors and Role in Predicting Hematologic Toxicity to PRRT and Chemotherapy

  3. Fidelman et al. Abstract C-27 A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases


    Alpha PRRT is Coming


  4. Wahl et al. Abstract C-37 Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)

  5. Strosberg et al. Abstract C-16 Targeted Alpha Therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors

  6. Halperin et al. Abstract C-17 ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: Phase 1b safety/efficacy


    Novel Treatments/Treatment Combinations


  7. Chauhan et al. Abstract C-5 Once-daily Oral Paltusotine in the Treatment of Patients With Carcinoid Syndrome: Results From a Phase 2, Randomized, Parallel-Group Study

  8. D’Souza, Soulen et al. Abstract C-29 Initial Outcomes of Integrating Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 3 Liver-Dominant Metastatic Neuroendocrine Tumors


    Improving Our Understanding of NETs: Basic, Translational, and Epidemiologic Studies of NETs


  9. Liu and Yao: Abstract B-1 Development of innovative in vitro and in vivo patient[1]derived cancer models for translational studies in G1/G2 gastroenteropancreatic neuroendocrine tumors

  10. Estrada and Bergsland et al. Abstract O-2 Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF

Chauhan, A., Chan, K., Halfdanarson, T. R., Bellizzi, A. M., Rindi, G., O'Toole, D., Ge, P. S., Jain, D., Dasari, A., Anaya, D. A., Bergsland, E., Mittra, E., Wei, A. C., Hope, T. A., Kendi, A. T., Thomas, S. M., Flem, S., Brierley, J., Asare, E. A., Washington, K., … Shi, C. (2024). Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA: a cancer journal for clinicians, 74(4), 359–367. https://doi.org/10.3322/caac.21840


 

ABOUT NANETS


The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 10 presentations from the November 21-23, 2024 NANETS Symposium, there are many more noteworthy abstracts found (or listed) here:



While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers.


 

RESOURCES


WATCH


Dr. Will Pegna Discusses Highlights from the 2024 NANETS Symposium


LISTEN


Top 10 Highlights of the 2023 NANETS Symposium

Top 10 Highlights of the 2022 NANETS Symposium


 

DISCLAIMER


LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment.

 

THANK YOU TO OUR SPONSORS







bottom of page